Skip to main content
    T

    Taysha Gene Therapies Inc (TSHA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $4.06
    -0.04 (-0.98%)

    Market Cap: $1.34B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Taysha Gene Therapies Inc (TSHA) Earnings: Report Dates and Results

    Updated Nov 12, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Taysha Gene Therapies (TSHA) is expected to report earnings on Mar 17, 2027. In the quarter ended Sep 30, 2026, Taysha Gene Therapies reported EPS of -$0.10, above the -$0.14 estimate. It beat the EPS estimate in 3 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    36%(9/25)
    Avg Surprise
    +3.55%
    Streak
    1 Q

    Upcoming Estimates

    Reports Mar 17, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.13
    Range-$0.15 - -$0.12
    14 analysts
    Revenue Consensus
    $382.50K
    RangeN/A
    13 analysts
    Reports May 4, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.10
    Range-$0.13 - -$0.08
    3 analysts
    EPS Revisions
    0
    2
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.13+18.5%
    60d ago-$0.12+16.2%
    30d ago-$0.12+16.2%
    7d ago-$0.12+16.2%
    Current-$0.10
    Revenue Consensus
    $1.60M
    RangeN/A
    3 analysts

    Next Report

    TSHA has an expected report date of Mar 17, 2027.

    TSHA Earnings Call

    The latest TSHA earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 25 quarters below that had an estimate, TSHA beat 9, missed 13 and matched 3. The widest gap in the table came in the quarter ended Dec 31, 2023, when EPS landed 936.36% above the estimate.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.10-$0.14-$0.14 - -$0.10+28.57%BeatN/A40 up, 3 downNov 12, 2026N/A
    Jun 30, 2026-$0.13-$0.11-$0.12 - -$0.09-18.18%MissN/A41 up, 0 downAug 11, 2026N/A
    Mar 31, 2026-$0.11-$0.10-$0.12 - -$0.07-10.00%MissN/A51 up, 0 downMay 6, 2026N/A
    Dec 31, 2025-$0.07-$0.10-$0.12 - -$0.07+23.43%BeatN/A51 up, 0 downMar 19, 2026$5.49M
    Sep 30, 2025-$0.09-$0.09-$0.12 - -$0.060.00%In lineN/A5N/ANov 4, 2025N/A
    Jun 30, 2025-$0.08-$0.07-$0.09 - -$0.05-14.29%MissN/A41 up, 0 downAug 12, 2025$1.99M
    Mar 31, 2025-$0.08-$0.08-$0.10 - -$0.080.00%In lineN/A21 up, 0 downMay 15, 2025$2.30M
    Dec 31, 2024-$0.07-$0.08N/A+12.50%Beat-107.6%N/A0 up, 0 downFeb 26, 2025$2.02M
    Sep 30, 2024-$0.07-$0.09-$0.11 - -$0.08+22.22%BeatN/A100 up, 0 downNov 13, 2024$1.79M
    Jun 30, 2024-$0.09-$0.10-$0.80 - -$0.08+10.00%BeatN/A112 up, 0 downAug 12, 2024$1.11M
    Mar 31, 2024-$0.10-$0.09-$0.19 - -$0.07-11.11%MissN/A100 up, 0 downMay 14, 2024$3.41M
    Dec 31, 2023$0.92-$0.11-$0.24 - -$0.07+936.36%BeatN/A100 up, 0 downMar 19, 2024$3.60M
    Sep 30, 2023-$0.93-$0.17-$0.31 - -$0.09-447.06%MissN/A100 up, 0 downNov 14, 2023$4.75M
    Jun 30, 2023-$0.38-$0.31-$0.39 - -$0.20-22.58%MissN/A90 up, 0 downAug 14, 2023$2.40M
    Mar 31, 2023-$0.28-$0.38-$0.39 - -$0.25+26.32%BeatN/A100 up, 0 downMay 11, 2023$4.71M
    Dec 31, 2022-$0.99-$0.33-$0.57 - $0.48-200.00%MissN/A130 up, 0 downMar 28, 2023$2.50M
    Sep 30, 2022-$0.64-$0.82-$0.99 - -$0.66+21.95%BeatN/A142 up, 0 downNov 8, 2022N/A
    Jun 30, 2022-$0.84-$1.06N/A+20.75%BeatN/AN/A0 up, 0 downAug 11, 2022N/A
    Mar 31, 2022-$1.31-$1.10-$1.43 - -$0.75-19.09%MissN/A150 up, 0 downMay 16, 2022N/A
    Dec 31, 2021-$1.32-$1.25-$1.62 - -$0.96-5.60%MissN/A16N/AMar 31, 2022N/A
    Sep 30, 2021-$1.35-$1.09-$1.28 - -$0.93-23.85%MissN/A120 up, 1 downNov 10, 2021N/A
    Jun 30, 2021-$1.09-$0.86-$0.95 - -$0.63-26.74%MissN/A12N/AAug 16, 2021N/A
    Mar 31, 2021-$0.87-$0.65-$0.74 - -$0.17-33.85%MissN/A6N/AMay 11, 2021N/A
    Dec 31, 2020-$1.04-$0.37-$0.58 - -$0.17-181.08%MissN/A4N/AMar 3, 2021N/A
    Sep 30, 2020-$1.28$0.07N/AN/AN/AN/A2N/ANov 12, 2020N/A
    Jun 30, 2020-$1.28-$1.28N/A0.00%In lineN/AN/AN/ASep 25, 2020N/A
    Last 26 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$0.32, after -$0.33 the year before. It was -$3.60 for the year ended Dec 31, 2020, the oldest of the 6 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$0.32N/A
    Dec 31, 2024-$0.33N/A
    Dec 31, 2023-$0.67N/A
    Dec 31, 2022-$3.78N/A
    Dec 31, 2021-$4.63N/A
    Dec 31, 2020-$3.60N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 8,600 words across 17 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20268,57417
    2026Q2Jun 30, 20266,42816
    2026Q1Mar 31, 20268,38017
    2025Q4Dec 31, 20258,82815
    2025Q3Sep 30, 20257,05815
    2025Q2Jun 30, 20255,58013
    2025Q1Mar 31, 20257,04016
    2024Q4Dec 31, 20244,36412

    2026Q3 Earnings Call

    Opening remarks

    Stephanie Webster Conference Call Host Thank you. Good morning, and welcome to Taysha's Third Quarter 2026 Financial Results and Corporate Update Conference Call. Earlier today, Taysha issued a press release announcing financial results for the quarter ended September 30, 2026. A copy of this press release is available on the company's website and through our SEC filings. Joining me on today's call are Sean Nolan, Taysha's Chief Executive Officer; Sukumar Nagendran, President and Head of R&D; and Kamran Alam, Chief Financial Officer. We will hold a question-and-answer session following our prepared remarks. On today's call, we will be making forward-looking statements, including statements concerning the potential of TSHA-102, including the reproducibility and durability of any favorable results initially seen in patients dosed to date in clinical trials, including with respect to functional milestones, to positively impact quality of life and alter the course of disease in the patients we seek to treat; our research, development, and regulatory plans for our product candidates, including the timing of initiating additional trials, reporting data from our clinical trials, and making regulatory submissions; the timing or outcomes of communications with the FDA on the regulatory pathway for TSHA-102; the potential for the product candidate to receive regulatory approval from the FDA or equivalent foreign regulatory agencies; our ability to realize the benefits of Breakthrough Therapy designation for TSHA-102; our ability to drive long-term value for stockholders; and the market opportunity for our program. This call may also contain forward-looking statements relating to Taysha's growth, forecasted cash runway, and future operating results; discovery and development of product candidates, including our potential nomination of an additional gene therapy candidate in the first half of 2027; manufacturing and commercial readiness activities; strategic alliances; and intellectual property, as well as matters that are not historical facts or information. Various risks may cause Taysha's actual results to differ materially from those stated or implied in such forward-looking statements. For a list and description of the risks and uncertainties that we face, please see the reports we have filed with the SEC, including our annual report on Form 10-K for the full year ended December 31, 2025, which we filed on March 19, 2026. This conference call contains time-sensitive information that is accurate only as of the date of this live broadcast, November 12, 2026. Taysha undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this conference call, except as may be required by applicable securities laws. With that, I would now like to turn the call over to our CEO, Sean Nolan.

    Sean Nolan CEO Thank you, Stephanie, and welcome, everyone, to our Third Quarter 2026 Financial Results and Corporate Update Conference Call.

    Frequently Asked Questions About TSHA

    When is Taysha Gene Therapies's next earnings date?

    Taysha Gene Therapies's next earnings report is expected for Mar 17, 2027.

    Did TSHA beat earnings estimates last quarter?

    Yes. Taysha Gene Therapies reported EPS of -$0.10 for the quarter ended Sep 30, 2026, above the -$0.14 estimate, a 28.57% surprise.

    What EPS do analysts expect from TSHA next quarter?

    The consensus EPS estimate for Taysha Gene Therapies for the quarter ending Dec 31, 2026 is -$0.13 from 14 analysts, with estimates from -$0.15 to -$0.12.

    How often does TSHA beat earnings estimates?

    Taysha Gene Therapies beat the EPS estimate in 3 of the last 8 quarters, with an average surprise of +2.75%.